

following VEGF downregulation via SRPK inhibition with SRPIN340. Therefore, SRPK inhibition with SRPIN340 could disrupt the vicious cycle formed by VEGF and its related proteins such as MCP-1 and ICAM-1, and result in the attenuation of CNV formation, suggesting the possibility of a novel chemical treatment strategy for pathological angiogenesis, which targets SRPK.

ACKNOWLEDGMENTS

The authors thank Ikuyo Hirose and Shiho Namba for their skillful technical assistance. This study was supported by the Advanced research for medical products Mining Programme of the National Institute of Biomedical Innovation (NIBIO) and Grant-in-Aid for Scientific Research (C; 23,592,547) of the Japan Society for the Promotion of Science.

REFERENCES

1. Seddon JM, Chen CA. The epidemiology of age-related macular degeneration. *Int Ophthalmol Clin* 2004; 44:17-39. [PMID: 15577562].
2. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. *Invest Ophthalmol Vis Sci* 1995; 36:182-91. [PMID: 7822146].
3. Klein R. Overview of progress in the epidemiology of age-related macular degeneration. *Ophthalmic Epidemiol* 2007; 14:184-7. [PMID: 17896295].
4. Brown MM, Brown GC, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR. The burden of age-related macular degeneration: a value-based analysis. *Curr Opin Ophthalmol* 2006; 17:257-66. [PMID: 16794438].
5. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. *Surv Ophthalmol* 1988; 32:375-413. [PMID: 2457955].
6. Spilisbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. *Am J Pathol* 2000; 157:135-44. [PMID: 10880384].
7. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. *Retina* 2006; 26:383-90. [PMID: 16603955].
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004; 351:2805-16. [PMID: 15625332].
9. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006; 355:1419-31. [PMID: 17021318].
10. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. *Nat Med* 2003; 9:781-8. [PMID: 12730690].
11. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? *Nat Rev Cancer* 2008; 8:880-7. [PMID: 18923433].
12. Cáceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. *Trends Genet* 2002; 18:186-93. [PMID: 11932019].
13. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. *J Cell Sci* 2008; 121:3487-95. [PMID: 18843117].
14. Fukuhara T, Hosoya T, Shimizu S, Sumi K, Oshiro T, Yoshinaka Y, Suzuki M, Yamamoto N, Herzenberg LA, Herzenberg LA, Hagiwara M. Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. *Proc Natl Acad Sci USA* 2006; 103:11329-33. [PMID: 16840555].
15. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR, Bates DO. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. *J Biol Chem* 2010; 285:5532-40. [PMID: 19906640].
16. Kuroyanagi N, Onogi H, Wakabayashi T, Hagiwara M. Novel SR-protein-specific kinase, SRPK2, disassembles nuclear speckles. *Biochem Biophys Res Commun* 1998; 242:357-64. [PMID: 9446799].
17. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; 25:402-8. [PMID: 11846609].
18. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. *Eur J Immunol* 1981; 11:805-15. [PMID: 7308288].
19. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. *Ophthalmology* 2009; 116:362- [PMID: 19187826].
20. Semeraro F, Morescalchi F, Parmeggiani F, Arcidiacono B, Costagliola C. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration. *Curr Vasc Pharmacol* 2011; 9:629-46. [PMID: 21470108].
21. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. *Nat Rev Cancer* 2007; 7:475-85. [PMID: 17522716].
22. Cunningham ET Jr, Feiner L, Chung C, Tuomi L, Ehrlich JS. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular

- degeneration. *Ophthalmology* 2011; 118:2447-52. [PMID: 21872935].
23. Garg S, Brod R, Kim D, Lane RG, Maguire J, Fischer D. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. *Clin Experiment Ophthalmol* 2008; 36:252-6. [PMID: 18412594].
 24. Bakkour N, Lin YL, Maire S, Ayadi L, Mahuteau-Betzer F, Nguyen CH, Mettling C, Portales P, Grierson D, Chabot B, Jeanteur P, Branlant C, Corbeau P, Tazi J. Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. *PLoS Pathog* 2007; 3:1530-9. [PMID: 17967062].
 25. Karakama Y, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Nishimura-Sakurai Y, Kakinuma S, Oooka M, Azuma S, Tsuchiya K, Onogi H, Hagiwara M, Watanabe M. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. *Antimicrob Agents Chemother* 2010; 54:3179-86. [PMID: 20498328].
 26. Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS, Bulla M, Royer-Pokora B. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. *J Am Soc Nephrol* 2007; 18:719-29. [PMID: 17267748].
 27. Rennel E, Waite E, Guan H, Schuler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. *Br J Cancer* 2008; 98:1250-7. [PMID: 18349828].
 28. Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zacheo O, Hassan AB, Harper SJ, Bates DO. VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. *Br J Cancer* 2008; 98:1366-79. [PMID: 18349829].
 29. Perrin RM, Konopatskaya O, Qiu Y, Harper S, Bates DO, Churchill AJ. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. *Diabetologia* 2005; 48:2422-7. [PMID: 16193288].
 30. Amin EM, Oltean S, Hua J, Gammons MV, Hamdollah-Zadeh M, Welsh GI, Cheung MK, Ni L, Kase S, Rennel ES, Symonds KE, Nowak DG, Royer-Pokora B, Saleem MA, Hagiwara M, Schumacher VA, Harper SJ, Hinton DR, Bates DO, Ladomery MR. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. *Cancer Cell* 2011; 20:768-80. [PMID: 22172722].
 31. Tripathi V, Song DY, Zong X, Shevtsov SP, Hearn S, Fu XD, Dunder M, Prasanth KV. SRSF1 regulates the assembly of pre-mRNA processing factors in nuclear speckles. *Mol Biol Cell* 2012; 23:3694-706. [PMID: 22855529].
 32. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. *Genes Dev* 2009; 23:482-95. [PMID: 19240134].
 33. Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. *Blood* 2000; 96:34-40. [PMID: 10891427].
 34. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP. VEGF164 is proinflammatory in the diabetic retina. *Invest Ophthalmol Vis Sci* 2003; 44:2155-62. [PMID: 12714656].
 35. Yoshida S, Yoshida A, Ishibashi T, Elnor SG, Elnor VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. *J Leukoc Biol* 2003; 73:137-44. [PMID: 12525571].
 36. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* 1996; 87:3336-43. [PMID: 8605350].
 37. Tsutsumi C, Sonoda KH, Egashira K, Qiao H, Hisatomi T, Nakao S, Ishibashi M, Charo IF, Sakamoto T, Murata T, Ishibashi T. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. *J Leukoc Biol* 2003; 74:25-32. [PMID: 12832439].

Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. The print version of this article was created on 5 March 2013. This reflects all typographical corrections and errata to the article through that date. Details of any changes may be found in the online version of the article.

RESEARCH

Open Access

Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors

Takashi Kurihara^{1,2*}, Eri Sakurai², Masayasu Toyomoto³, Isao Kii³, Daisuke Kawamoto¹, Toshihide Asada¹, Tsutomu Tanabe², Megumu Yoshimura⁴, Masatoshi Hagiwara³ and Atsuro Miyata¹

Abstract

Background: The phylogenetically highly conserved CK1 protein kinases consisting of at least seven isoforms form a distinct family within the eukaryotic protein kinases. CK1 family members play crucial roles in a wide range of signaling activities. However, the functional role of CK1 in somatosensory pain signaling has not yet been fully understood. The aim of this study was to clarify the role of CK1 in the regulation of inflammatory pain in mouse carrageenan and complete Freund's adjuvant (CFA) models.

Results: We have used two structurally different CK1 inhibitors, TG003 and IC261. TG003, which was originally identified as a cdc2-like kinase inhibitor, had potent inhibitory effects on CK1 isoforms *in vitro* and in cultured cells. Intrathecal injection of either TG003 (1-100 pmol) or IC261 (0.1-1 nmol) dose-dependently decreased mechanical allodynia and thermal hyperalgesia induced by carrageenan or CFA. Bath-application of either TG003 (1 μ M) or IC261 (1 μ M) had only marginal effects on spontaneous excitatory postsynaptic currents (sEPSCs) recorded in the substantia gelatinosa neurons of control mice. However, both compounds decreased the frequency of sEPSCs in both inflammatory pain models.

Conclusions: These results suggest that CK1 plays an important pathophysiological role in spinal inflammatory pain transmission, and that inhibition of the CK1 activity may provide a novel strategy for the treatment of inflammatory pain.

Keywords: Allodynia, Carrageenan, Complete Freund's adjuvant, CFA, Hyperalgesia, Whole-cell patch-clamp

Background

Increased sensitivity to both noxious and non-noxious stimuli is a hallmark of persistent pain states following tissue injury and inflammation. This hypersensitivity is associated with both peripheral and spinal neuronal plasticities, leading to a reduction of activation threshold in peripheral nociceptive sensory neurons in the dorsal

root ganglion (DRG) and trigeminal ganglion, as well as an increase in the synaptic activity between sensory nerve endings and second-order neurons in the spinal dorsal horn [1-3]. Inflammatory pain is typically treated with opioids and non-steroidal anti-inflammatory drugs such as cyclooxygenase 2 inhibitors. However, these treatments are currently limited by well-known side effects. Acute opioid treatment produces respiratory depression, sedation, nausea, constipation and vomiting, and long-term treatment with opioids and cyclooxygenase 2 inhibitors is associated with the development of addiction and cardiovascular defects, respectively. Thus, chronic pain associated with inflammation is still difficult to treat, and development of new strategies leading

* Correspondence: tkmphm10@m.kufm.kagoshima-u.ac.jp

¹Department of Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8544, Japan

²Department of Pharmacology and Neurobiology, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

Full list of author information is available at the end of the article



to pharmacological treatment of inflammatory pain is eagerly awaited.

Casein kinases (CK) were one of the first serine/threonine protein kinases to be identified and characterized in the 1970s [4-7]. Two distinct CK activities were recognized, leading to the identification of two different kinases, CK1 and CK2. Whereas CK2 belongs to the CMGC (cyclin-dependent kinase, mitogen-activated protein kinase, glycogen synthase kinase, CDC-like kinase) group, CK1 forms one of the eight major groups of protein kinases identified in the human and mouse genomes [8,9]. The CK1 family consists of several isoforms that include CK1 α , CK1 γ 1-CK1 γ 3, CK1 δ , and CK1 ϵ and their various splice variants. CK1 is present in different cell types and in subcellular compartments, including the plasma membrane, cytosol, and nucleus. The widespread distribution of CK1 suggests important regulatory roles of this protein kinase. At present, CK1 has been implicated in diverse biological processes including circadian rhythms, membrane trafficking, cytoskeleton maintenance, DNA and RNA metabolism [4-6]. However, the function of CK1 in the somatosensory pathway has not yet been fully examined.

IC261 is a commonly used and commercially available CK1 inhibitor, which is reported to be relatively specific for CK1 δ and ϵ isoforms [10], although some of its effects are likely to be independent from CK1 inhibition [11]. Previously we demonstrated that intrathecal administration of IC261 effectively reversed neuropathic pain-like behavior in mice [12]. TG003 originally identified as a *cdc2*-like kinase (Clk) inhibitor [13,14], has recently been shown to inhibit CK1 δ and ϵ activities equally to, or more potently than IC261 *in vitro* [15,16]. In this study, we examined the effects of these two structurally different CK1 specific inhibitors on inflammatory pain induced by peripheral treatment of carrageenan or CFA. A preliminary report of this study has been presented elsewhere [17].

Results

Evaluation of TG003 as an inhibitor of CK1 family members

We first verified the inhibitory effect of TG003 on the enzymatic activity of CK 1 family members and compared it with that of IC261. Recombinant CK1 α , δ , ϵ , γ 1, γ 2 or γ 3 were incubated with the substrate peptide CKtide in the presence of different concentrations of TG003 or IC261, respectively. Both small molecules inhibited CK1 family members in a dose-dependent manner (Figure 1). Inhibition of CK1 α , δ and ϵ by TG003 were equivalent to that by IC261. On the other hand, the inhibitory activities of TG003 on the kinase activity of CK1 γ 1, γ 2 and γ 3 were 20-fold or more higher than those of IC261 (Figure 1). These results


indicate that TG003 and IC261 are able to suppress the kinase activity of broad CK1 family members equally.

TG003 inhibited CK1 δ and ϵ -induced nuclear translocation of PER3

We next examined whether TG003 inhibits CK1 δ and ϵ in living cells. To quantify the kinase activity of CK1 δ and ϵ , we utilized CK1-induced nuclear translocation of PER3. PER3 is one of the mammalian homologues of *period*, which is a core molecular component of circadian rhythm and is involved in transcription-translation oscillatory feedback loops on the molecular level in the hypothalamic suprachiasmatic nucleus, the master pacemaker regulating circadian rhythms [4,18]. Phosphorylation of PER3 by CK1 δ and/or CK1 ϵ in the cytoplasm induces their translocation to the nucleus [19]. We constructed a constitutive expression vector of PER3 fused with mCherry (mCherry-PER3), and cloned both CK1 δ and CK1 ϵ under control of a doxycycline-inducible promoter. HEK293 cells were transfected with these recombinant vectors, and stable cell lines expressing both mCherry-PER3 and CK1 were established (Figure 2A, B). In the absence of doxycycline, fluorescence signals of mCherry-PER3 were mainly detected in the cytoplasm. Treatment with doxycycline for 8 hours, which triggered the expression of CK1 δ and ϵ , respectively, induced nuclear accumulation of mCherry-PER3. Co-administration of TG003 with doxycycline inhibited the nuclear translocation of mCherry-PER3. Similarly, the CK1 specific small molecule inhibitor, PF-670462, which was used as positive control [20], also inhibited the nuclear translocation (Figure 2A, B). On the other hand, a structurally similar compound TG001 [13], which possesses no inhibitory effect on CK1 δ and ϵ in the *in vitro* assay (data not shown), did not prevent the nuclear translocation of mCherry-PER3. To quantify the inhibitory effects on the nuclear translocation, we measured the fluorescence intensities of mCherry in the nucleus and cytoplasm by compartmental analysis using Cellomics BioApplications software for 20 images of each one, and calculated the mCherry-PER3 nuclear/cytoplasmic ratio as described in Methods. The ratio was significantly decreased upon TG003 or PF-670462, compared to that upon TG001 or vehicle treatment (Figure 2C, D), indicating that TG003 inhibits the function of CK1 δ and ϵ in living cells.

Intrathecal injection of IC261 or TG003 attenuated acute and persistent inflammatory pain behaviors

To investigate whether CK1 is involved in the inflammatory pain states, we evaluated the effects of IC261 or TG003 in mouse models of inflammatory pain. I.t. injections of IC261 (0.1-1 nmol) or TG003 (0.1-100 pmol) dose-dependently increased both withdrawal threshold and withdrawal latency of the hind paw ipsilateral to



carrageenan or CFA-induced inflammation (Figures 3 and 4). Spinal preemptive treatment of IC261 also dose-dependently attenuated the development of thermal hyperalgesia induced by carrageenan (Figure 3B). Thus, blocking the CK1 activity at the spinal level appeared to be effective in reduction of inflammation-induced mechanical allodynia and thermal hyperalgesia. The maximum effects were observed 0.5-1 hour after the injections of both inhibitors and significant analgesic effects were still observed 3-4 hours after the injection of the highest doses used in this study (Figures 3 and 4). These inhibitors had no significant effects on the contralateral hind paw (Figures 3 and 4). I.t. injection of vehicle (1% DMSO in saline) used as a solvent for the drugs did not show any effects (Figures 3A and 4B, data not shown).

Carrageenan- and CFA-induced inflammation did not upregulate CK1 α , δ and ϵ protein expression


We next examined the protein expression levels of CK1 α , δ and ϵ protein in the spinal cord (L4-6) and DRGs (L4-6) by immunoblot analyses. Expression of the three CK1 isoforms were not significantly altered in both spinal cord (carrageenan model: CK1 α , 95.6 \pm 11.2% of control, n = 6; CK1 δ , 143.4 \pm 25.0%, n = 11; CK1 ϵ , 101.7 \pm 9.25%, n = 6; CFA model : CK1 α , 108.7 \pm 18.3%, n = 6; CK1 δ , 99.7 \pm 13.7%, n = 11; CK1 ϵ , 93.6 \pm 10.8%,

n = 6) and DRGs (carrageenan model: CK1 α , 111.4 \pm 23.2% of control, n = 6; CK1 δ , 125.4 \pm 33.4%, n = 7; CK1 ϵ , 109.8 \pm 23.1%, n = 6; CFA model: CK1 α , 92.4 \pm 18.3% of control, n = 6; CK1 δ , 102.2 \pm 4.99%, n = 7; CK1 ϵ , 96.8 \pm 11.0%, n = 6) after carrageenan (6 hours)- or CFA (3 days)-treatment, respectively (see also Additional file 1).

IC261 and TG003 decreased the frequency of sEPSCs in inflammatory pain model mice

To explore the mechanism of the antinociception induced by IC261 or TG003 at the spinal level, we prepared L5 spinal cord slice preparation from adult mice (7-10 weeks old) and performed patch-clamp recordings in lamina II SG neurons ipsilateral to carrageenan, CFA, or vehicle injection [21-23]. The SG neurons of the spinal dorsal horn play an important role in the transmission and modulation of nociceptive information from the periphery to the CNS [24-26], and is one of the key sites generating synaptic plasticity (central sensitization) after tissue injury [3,26,27]. Such plasticity is exhibited in part as changes in spontaneous excitatory and inhibitory postsynaptic currents (sEPSCs and sIPSCs, respectively), which could point out both presynaptic mechanisms (frequency changes) and postsynaptic mechanisms (amplitude changes) [28-32].

We first examined the passive membrane properties of SG neurons. All SG neurons examined had resting




potentials more negative than -50 mV in control and two inflammatory pain model mice. No differences were found in the resting membrane potential and input membrane resistance among the groups (Additional file 2).

Next we characterized sEPSCs, recorded under voltage-clamp at a holding potential of -70 mV, from control and inflamed mice (Additional file 3A). The mean amplitude of sEPSCs was not significantly different among the groups. The mean frequency of sEPSCs, on the other hand, was

significantly different. We found that the average frequency but not the amplitude of sEPSCs was significantly increased in mice inflamed with CFA 3 days before, although carrageenan inflammation did not increase both the average sEPSC frequency and amplitude 6 hours after the injection.

We further examined sIPSCs from control and inflamed mice SG neurons at holding potentials of 0 mV (Additional file 3B). Although the mean amplitude of




sIPSCs was not different among the groups, the mean frequency of sIPSCs was significantly reduced in CFA groups.

We then examined the possibility that the observed effects of the two CK1 inhibitors originate from the regulation of the excitatory and inhibitory synaptic transmission in lamina II of inflamed mice. Superfusion of spinal cord slices from control mice either treated with IC261 (1 μ M) or TG003 (1 μ M) altered neither the frequency nor the amplitude of sEPSCs (Figures 5A and 6A). However, both CK1 inhibitors significantly suppressed sEPSCs recorded from carrageenan (Figures 5B and 6B)- or CFA (Figures 5C and 6C)-treated mice. It should be noted, however, that the inhibitory effects on sEPSC frequencies were much more dramatic than those on sEPSC amplitudes (Figures 5D and 6D), and furthermore, the magnitude

of inhibitory effects induced by TG003 on sEPSC frequencies was significantly higher than that induced by IC261 (Figures 5D and 6D) in both carrageenan and CFA treated animals. On the other hand, IC261 (1 μ M) did not affect sIPSCs from the inflamed mice, although slight but significant reduction of the mean amplitude of control sIPSCs was observed (Figure 7).

Discussion

The present study showed for the first time that the two structurally different CK1 inhibitors effectively reversed mechanical allodynia and thermal hyperalgesia induced by acute or persistent hindpaw inflammation. From *in vitro* whole-cell patch-clamp studies, a part of the analgesic mechanisms was suggested to be due to the inhibitory effects of the CK1 inhibitors on excitatory



synaptic transmission within SG neurons of the inflamed mice.


Pharmacological properties of IC261 and TG003

In this study we clarified that both IC261 and TG003 equally blocked CK1 α , δ and ϵ activities. We also identified that TG003 effectively blocked activities of CK1 γ isoforms. IC261 was initially reported as a selective CK1 δ/ϵ inhibitor which blocked CK1 δ and ϵ enzymatic activities more potently than CK1 α activity [10]. However, our *in vitro* kinase assay and a recent report [16] indicated that IC261 exerted comparable inhibitory effects against CK1 α , δ and ϵ isoforms, but inhibitory effects on three CK1 γ isoforms were relatively weak. In contrast, TG003 demonstrated almost equal inhibitory effects among CK1 isoforms. Results from our preliminary screening experiments and reports from other groups [15,16] suggested that common targets for IC261 and TG003 are CK1 α , δ and ϵ at this moment. Although

relative importance of each CK1 isoform in the allodynia and hyperalgesia remains to be determined, CK1 might play an important role for the development and maintenance of inflammatory pain.

One important finding of this study is that TG003 produced antinociceptive effects on both carrageenan- and CFA-induced inflammatory pain models at lower doses than IC261. This difference may be due to the fact that TG003 also blocks CK1 γ isoforms and Clks. In particular, IC₅₀ values of TG003 against Clk1 and 4 isoforms (15-20 nM) [13] are smaller than those against CK1 isoforms. However, it remains to be determined whether activation of CK1 γ isoforms and/or Clks significantly contributes to the pathogenic mechanism of pain. In addition, we could not exclude the possibility that other CK1-independent effects of TG003 and/or IC261 might affect the antinociceptive effects.

It would be noteworthy that TG003 preferentially alleviated mechanical allodynia than thermal hyperalgesia in




both carrageenan and CFA models. Although 1 pmol of TG003 did not affect CFA-induced thermal hyperalgesia, the same dosage of TG003 significantly reversed CFA-induced mechanical allodynia. IC261, on the other hand, was shown to be equally effective on both mechanical allodynia and thermal hyperalgesia in the present inflammatory pain models, as well as in our previously described spinal nerve injury model [12]. The reason of this difference is currently unknown and further rigorous studies would be necessary to evaluate the pharmacological profiles of TG003 and IC261.

Inhibition of pain-related synaptic plasticity by the CK1 inhibitors

Since intrathecal injection of these CK1 inhibitors reversed both mechanical and thermal nociceptive behaviors after peripheral inflammation, we investigated whether bath application of these CK1 inhibitors affects on sEPSCs and/or sIPSCs by using the whole-cell patch-clamp method in SG neurons of adult spinal cord slices.

First, we characterized the effects of carrageenan- or CFA-induced peripheral inflammation on the sEPSCs and sIPSCs. In general accordance with previous reports [28,33,34], we found that CFA inflammation for 3 days elicited significant increase in mean frequency of sEPSCs, and significant decrease of mean frequency, but not amplitude, of sIPSCs. In contrast, significant changes in frequencies and amplitudes of sEPSCs and sIPSCs were not observed 6 hours after carrageenan injection, which may be consistent with the previous report showing no alteration in frequencies and amplitudes of miniature EPSCs and IPSCs 1-2 days after carrageenan inflammation in immature rats [35]. One apparent difference between our present data and the previous report using mice CFA model [28] is that we could not detect significant increase in the mean amplitude of sEPSCs after CFA inflammation. The reason for this difference is at present unknown, but this might be due to the difference (this study vs. [28]) of strain (C57BL/6J vs. CD1), age (7-10 weeks old vs. 4-6 weeks old) or duration after CFA injection (3 days vs. 1 day).




More importantly, we found that bath-application of IC261 or TG003 had no effects on sEPSCs from control animals, but carrageenan and CFA inflammation turned the CK1 inhibitors effective in decreasing the mean frequencies of their respective sEPSCs. Since we did not characterize the SG neurons we recorded by anatomical and more detailed electrophysiological criteria [36,37] in this study, it is currently difficult to discuss possible involvement of CK1 in the superficial dorsal horn synaptic circuits. However, it may be worth noting here that both IC261 and TG003 exerted relatively consistent inhibitory effects on sEPSCs in the inflammatory pain models. In any case, this observation suggests that the nature of sEPSCs recorded in inflamed mice seems to be very different from those found in control animals. Our previous report also demonstrated similar specific inhibitory effects of IC261 on excitatory responses in dorsal horn elicited by dorsal root electrical stimulation only in spinal nerve injured but not in sham operated mice [12]. These results also seem to be consistent with the facts that these CK1 inhibitors dampen inflammatory (this

study) and neuropathic (our previous study) pain-like behaviors without showing any appreciable effects on contralateral hindpaws.

Interestingly, we noticed a significant difference between IC261 and TG003 on inflamed mice, that is, 1 μ M of TG003 had more potently inhibited the mean frequency of sEPSCs than the same concentration of IC261. At present, we could only speculate that the difference in their potencies might be derived from the distinct actions of TG003 on CK1 isoforms and/or Clks as described above, but further study is needed to verify this possibility.

The preferential inhibitory effects of IC261 and TG003 on the frequency of sEPSCs might suggest pre- rather than post-synaptic site of action of these molecules in SG synapses and this inhibitory modulation would contribute the antinociceptive effects on inflamed mice. It is generally believed that changes in the frequency and amplitude of sEPSCs are mediated by respective pre- and post-synaptic mechanisms [28-32]. We previously suggested that similar mechanism would be involved in the antinociceptive effects of CK1 inhibitors on neuropathic



pain-like behaviors [12]. CK1 isoforms were shown to be associated with cytosolic vesicles including small synaptic vesicles and to phosphorylate several small synaptic vesicle-associated proteins in neuronal cells [38-40], suggesting a possible involvement of CK1 in the synaptic vesicle exocytosis [5,40].

At least CK1δ [41] and ε [12,42] proteins are shown to be expressed in mouse spinal dorsal horn neurons and primary sensory neurons at normal state. In contrast to our previous results that upregulation of CK1ε protein expression was observed in the spinal dorsal horn (L5) and injured L5 DRG neurons ipsilateral to the nerve injury in the mouse L5/6 spinal nerve injury model [12], we could not detect significant increases of protein expression levels of CK1α, δ, ε isoforms in the spinal cord (L4-6) and DRGs (L4-6) in the present immunoblot study as shown in Additional file 1. It would be, therefore, interesting to hypothesize that activity of CK1 in the primary sensory neurons and/or spinal dorsal horn neurons regulated by the peripheral inflammation would contribute to the

spinal plasticity which has an important role in generating inflammatory pain states. Several mechanisms, such as control of subcellular localization by regulating membrane and/or nuclear trafficking, and modulation of the inhibitory autophosphorylation sites located at C-terminal domains of CK1, which have been identified to modulate CK1 activity in other experimental conditions [5,6], might also be relevant to our present observation. Targeting mechanisms that counter-regulate the spinal consequences of peripheral inflammation by CK1 inhibitors or other methods may provide an effective way to control chronic pain. Further elucidation of CK1 signaling mechanisms including spatial distribution of CK1 isoforms before and after inflammation is considered to be critical in future clinical development for directing the signaling pathways with small molecule agents.

Conclusions

In summary, the present study suggests an important role of CK1 in inflammatory pain symptoms. Although the

specific role of each CK1 isoforms in inflammatory pain remains elusive, CK1 inhibitors could be promising new therapeutics for treating pain associated with inflammation as well as neuropathic pain.

Methods

In vitro kinase assay

The inhibitory effects of TG003 and IC261 against CK1 isoforms were tested using the QuickScout screening assist mobility shift assay with the ATP concentration at the *K_m* (4.1 μ M for CK1 α , 6.3 μ M for CK1 γ 1, 10 μ M for CK1 γ 2, 3.2 μ M for CK1 γ 3, 7.7 μ M for CK1 δ , and 16 μ M for CK1 ϵ ; Carna Biosciences, Inc., Kobe, Japan). Detailed information on the assay condition is available on the website of Carna Biosciences (<http://www.carnabio.com>). Full-length human CK1 α , CK1 γ 1, CK1 γ 2, CK1 γ 3 and catalytic domain of human CK1 ϵ were expressed as N-terminal GST-fusion protein using baculovirus system, and purified by using glutathione sepharose chromatography. Catalytic domain of CK1 δ was expressed as N-terminal GST-fusion protein in *E. coli*, and purified by using glutathione sepharose chromatography.

Vector construction

PCR-amplified fragments of mCherry (Clontech) and PER3 (Accession: NP_058515) were fused in-frame by overlap-extension PCR method to generate mCherry-PER3, respectively, as described previously [43] with some modifications. The combined fragment was inserted into pCAGIPuro vector, an IRES-based bicistronic expression vector where the gene of interest and a puromycin resistant gene are expressed from a single mRNA, which enables almost all of the cells selected with puromycin to express the gene product. PCR-amplified fragments of FLAG-tagged CK1 δ (Accession: BC015775) and ϵ (Accession: BC006490) were fused in-frame to the amino-terminus of EGFP via F2A peptide sequence by overlap-extension PCR method, which enables bicistronic expression of FLAG-tagged CK1 isoforms and EGFP. The combined fragments were inserted into pcDNA5/FRT/TO (Life Technologies). The reconstituted vector sequences are available upon request.

Cell culture and transfection

Flp-In/T-REx HEK293 cell (Life Technologies) was maintained in low glucose Dulbecco's modified Eagle's medium (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum (Nichirei Biosciences, Tokyo, Japan), 100 units/ml of penicillin and 100 μ g/ml of streptomycin (Nacalai Tesque). Cells were transfected with plasmid DNAs using polyethylenimine MAX (Polysciences) as described previously [44], and then selected with hygromycin B (Life Technologies) for pcDNA5/

FRT/TO vectors and puromycin (Nacalai Tesque) for pCAGIPuro vectors to establish the stable cell lines.

PER3 nuclear translocation assay

HEK293 cells seeded in a density of 1×10^5 cells/dish in polyethyleneimine-coated 35 mm glass bottom dishes (MatTek, Ashland, MA) were cultured for 2 days. Cells were pre-incubated with 0.1% dimethyl sulfoxide (DMSO) containing 30 μ M TG003, 30 μ M TG001, or 1 μ M PF-670462 (Merck, Darmstadt, Germany) for 1 hour at 37°C before expression of CK1 δ or CK1 ϵ was induced with 1 μ g/ml of doxycycline. After 8 hour incubation with doxycycline at 37°C, cells were fixed with 10% Formaldehyde Neutral Buffer Solution (Nacalai Tesque) for 10 min at room temperature. Cells were washed twice with PBS and then stained with 5 μ g/ml of Hoechst33342 (Dojindo, Kumamoto, Japan) in PBS for 30 min at room temperature. The Hoechst33342 solution was removed and cells were washed with PBS, and stored in 1.5 ml PBS at 4°C in the dark until taking fluorescent images on the Confocal Laser Scanning Biological Microscope FV10i (Olympus, Tokyo, Japan).

The fluorescent images were analyzed by the compartmental analysis algorithm predefined in Cellomics BioApplications (Thermo Fisher Scientific, Waltham, MA). The nuclear-cytoplasmic ratio of the mCherry-PER3 signal intensity was quantified by dividing the mean average mCherry intensity in the nuclear area defined as "circ" by the mean average mCherry intensity of a "ring" around this area, which covered a cytoplasmic region. The distance of the circ to the nuclear outline was 16 pixels. The ring had a width of 4 pixels and a distance of 1 pixel from the nuclear outline. The fluorescent image containing over 15 objects (cells) counted by the compartmental analysis algorithm was used for analysis. The objects that were under 650 of the mean average EGFP intensity in the nuclear area were excluded. Analysis data was exported into Excel file for statistical analysis.

Animals

Male C57BL/6 J mice (5 weeks old) were purchased from Clea Japan, Inc. (Tokyo, Japan) and housed under controlled temperature ($24 \pm 1^\circ\text{C}$) and humidity ($55 \pm 10\%$) with a 12-hour light-dark cycle with food and water freely available. The animal experiments were approved by the Animal Care Committees of Tokyo Medical and Dental University (approval No. 0090173) and Kagoshima University (approval No. MD10053), and were conducted in accordance with the ethical guidelines for the study of experimental pain in conscious animals published by the International Association of the Study of Pain (1995) [45] and the European Communities Council Directive of 24 November, 1986 (86/609/EEC).

Animal models and behavioral studies

To produce acute and persistent inflammatory pain, carrageenan (2% lambda carrageenan in saline, 25 μ l, Sigma, St. Louis, MO) and complete Freund's adjuvant (CFA, 25 μ l, Sigma) were injected into the plantar surface of the right hindpaw under light halothane anesthesia, respectively [46-49]. Control mice were treated with saline or incomplete Freund's adjuvant (IFA, Sigma), respectively. Mechanical allodynia and thermal hyperalgesia were measured using the Dynamic Plantar Aesthesiometer (Ugo Basile, Comerio VA, Italy) and the Paw Thermal Stimulator (UCSD, San Diego, CA, USA), respectively as described [12]. In CFA model, these behavioral experiments were conducted 3 days after the injection. Intrathecal (i.t.) injection was given in a volume of 5 μ l by percutaneous puncture through an intervertebral space at the level of the 5th or 6th lumbar vertebra, according to a previously reported procedure [12,50]. An investigator, who was unaware of the drug treatment, performed all of the behavioral experiments.

Immunoblot analysis

Six hours after carrageenan or saline injection, and 3 days after CFA or IFA injection, mice were anesthetized with sodium pentobarbital (50 mg/kg), and the lumbar spinal cord and DRGs (L4-L6) were quickly removed. Each sample was homogenized in a lysis buffer [150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 1:100 diluted protease inhibitor cocktail (Sigma), and 50 mM Tris-HCl, pH 8.0]. Protein concentrations were determined with a Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Proteins were separated by SDS-PAGE (7.5% gel) and then transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). Anti-CK1 α (rabbit polyclonal, raised against amino acids 281-337 at the C-terminus of human CK1 α ; 1: 2,000; no. sc-28886, Santa Cruz Biotechnology, Santa Cruz, CA), anti-CK1 ϵ (rabbit polyclonal, raised against amino acids 301-360 near the C-terminus of human CK1 ϵ ; 1: 1,000; no. sc-25423, Santa Cruz Biotechnology) and anti-CK1 δ antibody (rabbit polyclonal, NC10, 1:4,000; kindly donated by Prof. Uwe Knippschild, Univ. Ulm, Germany) were used. The specificities of the three antibodies were characterized and reported previously in several studies including ours [12,41,42,51]. We have also conducted control staining experiments; omission of primary antibody or secondary antibody, and substitution of primary antibody with normal rabbit IgG. We did not obtain any signals from these control experiments (data not shown).

Immunoreactivity was detected by using the ECL system (GE Healthcare, Buckinghamshire, UK). An anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (mouse monoclonal, 1:20,000; no. MAB374, Chemicon, Temecula, CA) or β -actin (mouse monoclonal,

1:1,000; no. sc-47778, Santa Cruz Biotechnology) were used to normalize protein loading. Relative intensities of the bands were quantified by using an image analysis system with Image J software, version 1.40 g (National Institutes of Health, Bethesda, MD). At least two independent immunoblot experiments of three independent spinal cord and DRG samples were analyzed.

Patch-clamp recordings from spinal dorsal horn neurons

Adult mouse spinal cord slices were prepared according to the method of Yoshimura & Jessell [21,22]. Briefly, 6 hours after carrageenan or saline injection, and 3 days after CFA or IFA injection, transverse slices (thickness, 800-900 μ m) of the L5 spinal segments with the L5 dorsal root attached were cut on a vibrating blade microtome. The slices were superfused with Krebs solution (10-15 ml/min) saturated with 95% O₂ and 5% CO₂ at 36 \pm 1°C. The composition of Krebs solution was as follows (in mM): NaCl 117; KCl 3.6; NaHCO₃ 25; NaH₂PO₄ 1.2; CaCl₂ 2.5; MgCl₂ 1.2, and glucose 11 (pH 7.4 after gas saturation).

Blind whole-cell patch-clamp recordings were made from the lamina II (substantia gelatinosa: SG) neurons ipsilateral to carrageenan, CFA, or vehicle (saline or IFA) injection in voltage clamp mode. Patch pipettes were fabricated from thin-walled, borosilicate, glass-capillary tubing (1.5 mm o.d., World Precision Instruments). After establishing the whole-cell configuration, neurons were held at the potential of -70 mV to record spontaneous excitatory postsynaptic currents (sEPSCs) and at the potential of 0 mV to record spontaneous inhibitory postsynaptic currents (sIPSC). Under these conditions, GABA- and glycine-mediated IPSCs and glutamate-mediated EPSCs, respectively, were negligible, because these holding potential were close to the reversal potentials of IPSCs and EPSCs, respectively [52]. Recording electrodes were filled with either potassium gluconate-based solution (in mM: K-gluconate 135; KCl 5; CaCl₂ 0.5; MgCl₂ 2; EGTA 5; HEPES 5; ATP-Mg 5; adjusted with KOH to pH 7.2) to investigate EPSCs, or Cs-based solution (in mM: Cs₂SO₄ 110; tetraethylammonium 5; CaCl₂ 0.5; MgCl₂ 2; EGTA 5; HEPES 5; ATP-Mg 5; adjusted with CsOH to pH 7.2) to examine IPSCs. The resistance of a typical patch pipette is 5-10 M Ω . Membrane currents were amplified with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA) in voltage-clamp mode. Signals were low-pass filtered at 5 kHz and digitized at 333 kHz with an A/D converter (Digidata 1322, Molecular Devices). Data were stored with a personal computer using pCLAMP10 software and analyzed with Mini Analysis software (Synaptosoft Inc., Decatur, GA, USA).

The average values of both frequency and amplitude of sEPSCs or sIPSCs during the control (1 min) and 5-

10 min after the drug application (1 min period after the attainment of steady effect of each drug) were calculated and quantified as relative changes in frequency and amplitude. Since the characteristics of sEPSCs and sIPSCs parameters (frequency and amplitude) were not significantly different among naïve-, saline- and IFA-control, data from each control were combined.

Drugs

IC261 was from Calbiochem, LaJolla, CA, USA. PF-670462 was obtained from Tocris bioscience, Bristol, UK. TG003 and TG001 were synthesized according to the procedures described previously [13]. These drugs were made up as concentrated stock solution in DMSO, aliquoted and stored at -20°C . An aliquot was diluted to the desired concentration in saline or Krebs solution immediately prior to use. The dose ranges of IC261 and TG003 used were determined according to our previous report (for IC261) [12] and preliminary study (for TG003).

Statistical analysis

Experimental data are expressed as mean \pm SEM. Single comparisons were made using Student's two-tailed paired or unpaired *t*-test. One-way ANOVA followed by the Dunnett's or Tukey's test was used for multiple comparisons. $P < 0.05$ was considered statistically significant.

Additional files

Additional file 1: Carrageenan- and CFA-induced inflammation did not upregulate CK1 α , δ and ϵ expression. Immunoblot analyses of CK1 α (A), δ (B) and ϵ (C) expression levels in the spinal cord and DRGs. L4-6 spinal segments and DRGs ipsilateral to the inflammation were dissected 6 hours after carrageenan (Car) and 3 days after CFA injection. As a control, saline (Sal) and incomplete Freund's adjuvant (IFA) were injected instead of Car and CFA, respectively.

Additional file 2: Comparison of passive membrane properties among L5 SG neurons obtained from control and inflamed mice.

Additional file 3: Effects of inflammation on spontaneous EPSCs (sEPSCs, A) and IPSCs (sIPSCs, B). Hindpaw injection of CFA but not carrageenan (Car) increased mean frequency of sEPSCs and decreased mean frequency of sIPSCs. Neither CFA nor carrageenan changed mean amplitudes of sEPSCs and sIPSCs. Three days (CFA 3d) or 6 hours (Car 6 h) after injection, spinal cord slices were prepared and blind whole-cell patch-clamp recordings were made from the SG neurons ipsilateral to Car, CFA, or vehicle injection. * $P < 0.05$, ** $P < 0.01$; one-way ANOVA followed by Tukey's post hoc test.

Abbreviations

CFA: Complete Freund's adjuvant; CK: Casein kinase; Clk: cdc2-like kinase; DRG: Dorsal root ganglion; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; IFA: Incomplete Freund's adjuvant; i.t.: Intrathecal; sEPSC: Excitatory and inhibitory postsynaptic currents; sIPSC: Inhibitory postsynaptic currents; SG: Substantia gelatinosa.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TK participated in the design of the study, performed behavioral and electrophysiological studies and wrote the manuscript. ES, TA and DK carried out behavioral and immunoblot analysis. MT and IK performed in vitro kinase assay and molecular biological study and wrote the manuscript. TT, MY, MH and AM participated in the design of the study and reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors are grateful to Professor Uwe Knippschild (University of Ulm, Germany) for helpful comments on the manuscript and for kind donation of the CK1 δ antibody NC10. The authors also thank Drs. Kazuhiko Inoue and Yuki Kambe for helpful discussions. This work was supported by a Grant-in-Aid for Young Scientists (A), JSPS (14704022) and a Grant-in-Aid for Scientific Research (C), JSPS (22600001) to T.K. E.S. was supported by a grant from the MD/PhD Program of Tokyo Medical and Dental University, the 21st Century COE Program on Brain Integration and its Disorders to Tokyo Medical and Dental University, and Shouichi Kohashi Foundation.

Author details

¹Department of Pharmacology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima 890-8544, Japan. ²Department of Pharmacology and Neurobiology, Graduate School of Medicine, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. ³Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. ⁴Graduate School of Health Sciences, Kumamoto Health Science University, 325 Izumi-machi, Kumamoto 861-5598, Japan.

Received: 2 December 2013 Accepted: 2 March 2014

Published: 10 March 2014

References

1. Kuner R: Central mechanisms of pathological pain. *Nat Med* 2010, **16**:258–1266.
2. Dawes JM, Anderson DA, Bennett DLH, Bevan S, McMahon SB: Inflammatory mediators and modulators of pain. In *Wall and Melzack's Textbook of Pain*. 6th edition. Edited by McMahon SB, Koltzenburg M, Tracy I, Turk DC. Philadelphia, PA: Elsevier; 2013:48–67.
3. Sandkühler J: Spinal cord plasticity and pain. In *Wall and Melzack's Textbook of Pain*. 6th edition. Edited by McMahon SB, Koltzenburg M, Tracy I, Turk DC. Philadelphia, PA: Elsevier; 2013:94–110.
4. Gross SD, Anderson RA: Casein kinase I: spatial organization and positioning of a multifunctional protein kinase family. *Cell Signal* 1998, **10**:699–711.
5. Knippschild U, Gocht A, Wolff S, Huber N, Löhler J, Stöter M: The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. *Cell Signal* 2005, **17**:675–689.
6. Cheong JK, Virshup DM: Casein kinase 1: Complexity in the family. *Int J Biochem Cell Biol* 2011, **43**:465–469.
7. Perez DI, Gil C, Martinez A: Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. *Med Res Rev* 2011, **31**:924–954.
8. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S: The protein kinase complement of the human genome. *Science* 2002, **298**:1912–1934.
9. Caenepeel S, Charyczak G, Sudarsanam S, Hunter T, Manning G: The mouse kinome: discovery and comparative genomics of all mouse protein kinases. *Proc Natl Acad Sci U S A* 2004, **101**:11707–11712.
10. Mashhoon N, DeMaggio A, Tereshko V, Bergmeier SC, Egli M, Hoekstra MF, Kuret J: Crystal structure of a conformation-selective casein kinase-1 inhibitor. *J Biol Chem* 2000, **275**:20052–20060.
11. Cheong JK, Nguyen TH, Wang H, Tan P, Voorhoeve PM, Lee SH, Virshup DM: IC261 induces cell cycle arrest and apoptosis of human cancer cells via CK1 δ/ϵ and Wnt/ β -catenin independent inhibition of mitotic spindle formation. *Oncogene* 2011, **30**:2558–2569.
12. Sakurai E, Kurihara T, Kouchi K, Saegusa H, Zong S, Tanabe T: Upregulation of casein kinase 1 ϵ in dorsal root ganglia and spinal cord after mouse spinal nerve injury contributes to neuropathic pain. *Mol Pain* 2009, **5**:74.
13. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, Sumi K, Yomoda J, Murray MV, Kimura H, Furuichi K, Shibuya H, Krainer AR, Suzuki M, Hagiwara M: Manipulation of alternative splicing by a newly developed inhibitor of Clks. *J Biol Chem* 2004, **279**:24246–24254.

14. Nishida A, Kataoka N, Takeshima Y, Yagi M, Awano H, Ota M, Itoh K, Hagiwara M, Matsuo M: **Chemical treatment enhances skipping of a mutated exon in the dystrophin gene.** *Nat Commun* 2011, **2**:308.
15. Isojima Y, Nakajima M, Ukai H, Fujishima H, Yamada RG, Masumoto KH, Kiuchi R, Ishida M, Ukai-Tadenuma M, Minami Y, Kito R, Nakao K, Kishimoto W, Yoo SH, Shimomura K, Takao T, Takano A, Kojima T, Nagai K, Sakaki Y, Takahashi JS, Ueda HR: **CKI ϵ/δ -dependent phosphorylation is a temperature-insensitive, period-determining process in the mammalian circadian clock.** *Proc Natl Acad Sci U S A* 2009, **106**:15744–15749.
16. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson J: **Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.** *Nat Biotech* 2011, **29**:1039–1046.
17. Kurihara T, Sakurai E, Asada T, Miyata A, Tanabe T: **Activation of casein kinase 1 δ/ϵ in dorsal root ganglia and spinal cord contributes to behavioral hypersensitivity induced by inflammation in mice [abstract].** *J Pharmacol Sci* 2011, **115**(Suppl. 1):254P.
18. Ebisawa T: **Circadian rhythm in the CNS and peripheral clock disorders: Human sleep disorders and clock genes.** *J Pharmacol Sci* 2007, **103**:150–154.
19. Akashi M, Tsuchiya Y, Yoshino T, Nishida E: **Control of intracellular dynamics of mammalian period proteins by casein kinase 1 ϵ (CK1 ϵ) and CK1 δ in culture cells.** *Mol Cell Biol* 2002, **22**:1693–1703.
20. Badura L, Swanson T, Adamowicz W, Adams J, Cianfrogna J, Fisher K, Holland J, Kleiman R, Nelson F, Reynolds L, St Germain K, Schaeffer E, Tate B, Sprouse J: **An inhibitor of casein kinase 1 ϵ induces phase delays in circadian rhythms under free-running and entrained conditions.** *J Pharmacol Exp Ther* 2007, **322**:730–738.
21. Yoshimura M, Jessell TM: **Primary afferent-evoked synaptic responses and slow potential generation in rat substantia gelatinosa neurons in vitro.** *J Neurophysiol* 1989, **62**:96–108.
22. Yoshimura M, Jessell TM: **Amino-acid mediated EPSPs at primary afferent synapses with substantia gelatinosa neurons in the rat spinal cord.** *J Physiol (Lond)* 1990, **430**:315–335.
23. Yanagisawa Y, Furue H, Kawamata T, Uta D, Yamamoto J, Furuse S, Katafuchi T, Imoto K, Iwamoto Y, Yoshimura M: **Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord.** *Mol Pain* 2010, **6**:38.
24. Willis WD Jr, Coggeshall RE: *Sensory mechanisms of the spinal cord. Volume 1.* 3rd edition. New York: Kluwer Academic/Plenum Publishers; 2004.
25. Todd AJ, Koerber HR: **Neuroanatomical substrates of spinal nociception.** In *Wall and Melzack's Textbook of Pain*. 6th edition. Edited by McMahon SB, Koltzenburg M, Tracy I, Turk DC. Philadelphia, PA: Elsevier; 2013:77–93.
26. Latremoliere A, Woolf CJ: **Central sensitization: A generator of pain hypersensitivity by central neural plasticity.** *J Pain* 2009, **10**:895–926.
27. Ji R-R, Kohno T, Moore KA, Woolf CJ: **Central sensitization and LTP: do pain and memory share similar mechanisms?** *Trends Neurosci* 2003, **26**:696–705.
28. Park C-K, Xu Z-Z, Liu T, Lü N, Serhan CN, Ji R-R: **Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct role of Resolvin D1, D2, and E1.** *J Neurosci* 2011, **31**:18433–18438.
29. Yang K, Kumamoto E, Furue H, Yoshimura M: **Capsaicin facilitates excitatory but not inhibitory synaptic transmission in substantia gelatinosa of the rat spinal cord.** *Neurosci Lett* 1998, **255**:135–138.
30. Engelman HS, MacDermott AB: **Presynaptic ionotropic receptors and control of transmitter release.** *Nat Rev Neurosci* 2004, **5**:135–145.
31. Kawasaki Y, Zhang L, Cheng J-K, Ji R-R: **Cytokine mechanisms of central sensitization: Distinct and overlapping role of interleukin-1 β , interleukin-6, and tumor necrosis factor- α in regulating synaptic and neuronal activity in the superficial spinal cord.** *J Neurosci* 2008, **28**:5189–5194.
32. Xu Z-Z, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji R-R: **Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions.** *Nat Med* 2010, **16**:592–597.
33. Müller F, Heinke B, Sandkühler J: **Reduction of glycine receptor-mediated miniature inhibitory postsynaptic currents in rat spinal lamina I neurons after peripheral inflammation.** *Neuroscience* 2003, **122**:799–805.
34. Yang K, Takeuchi K, Wei F, Dubner R, Ren K: **Activation of group I mGlu receptors contributes to facilitation of NMDA receptor membrane current in spinal dorsal horn neurons after hind paw inflammation in rats.** *Eur J Pharmacol* 2011, **670**:509–518.
35. Li J, Baccei ML: **Excitatory synapses in the rat superficial dorsal horn are strengthened following peripheral inflammation during early postnatal development.** *Pain* 2009, **143**:56–64.
36. Yasaka T, Kato G, Furue H, Rashid MH, Sonohata M, Tamae A, Murata Y, Masuko S, Yoshimura M: **Cell-type-specific excitatory and inhibitory circuits involving primary afferents in the substantia gelatinosa of the rat spinal dorsal horn in vitro.** *J Physiol* 2007, **581**:603–618.
37. Yasaka T, Tiong SYX, Hughes DI, Riddell JS, Todd AJ: **Populations of inhibitory and excitatory interneurons in lamina II of the adult rat spinal dorsal horn revealed by a combined electrophysiological and anatomical approach.** *Pain* 2010, **151**:475–488.
38. Pyle RA, Schivell AE, Hidaka H, Bajjalieh SM: **Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin.** *J Biol Chem* 2000, **275**:17195–17200.
39. Takamori S, Holt M, Stenius K, Lemke E, Grønborg M, Riedel D, Urlaub H, Schenck S, Brügger B, Ringler P, Müller S, Rammner B, Gräter F, Hub JS, De Groot BL, Mieskes G, Moriyama Y, Klingauf J, Grubmüller H, Heuser J, Wieland F, Jahn R: **Molecular anatomy of a trafficking organelle.** *Cell* 2006, **127**:831–846.
40. Wolff S, Stöter M, Giamas G, Piesche M, Henne-Bruns D, Banting G, Knippschild U: **Casein kinase 1 delta (CK1 δ) interacts with the SNARE associated protein snapin.** *FEBS Lett* 2006, **580**:6477–6484.
41. Löhler J, Hirner H, Schmidt B, Kramer K, Fischer D, Thal DR, Leithäuser F, Knippschild U: **Immunohistochemical characterisation of cell-type specific expression of CK1 δ in various tissues of young adult BALB/c mice.** *PLoS ONE* 2009, **4**:e4174.
42. Utz CA, Hirner H, Blatz A, Hillenbrand A, Schmidt B, Deppert W, Henne-Bruns D, Fischer D, Thal DR, Leithäuser F, Knippschild U: **Analysis of cell type-specific expression of CK1 ϵ in various tissues of young adult BALB/c mice and in mammary tumors of SV40 T-Ag-transgenic mice.** *J Histochem Cytochem* 2010, **58**:1–15.
43. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR: **Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.** *Gene* 1989, **77**:61–68.
44. Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM: **Full deacylation of polyethyleneimine dramatically boosts its gene delivery efficiency and specificity to mouse lung.** *Proc Natl Acad Sci U S A* 2005, **102**:5679–5684.
45. International Association for the Study of Pain: **Animal models of pain and ethics of animal experimentation.** In *Core Curriculum for Professional Education in Pain*. Edited by Fields HL. Seattle: IASP Press; 1995:111–112.
46. Kayser V, Guilbaud G: **Local and remote modifications of nociceptive sensitivity during carrageenan-induced inflammation in the rat.** *Pain* 1987, **28**:99–107.
47. Iadarola MJ, Brady LS, Draisci G, Dubner R: **Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding.** *Pain* 1988, **45**:313–326.
48. Stein C, Millan MJ, Herz A: **Unilateral inflammation of the hind paw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds.** *Pharmacol Biochem Behav* 1988, **31**:445–451.
49. Sammons MJ, Raval P, Davey PT, Rogers D, Parsons AA, Bingham S: **Carrageenan-induced thermal hyperalgesia in the mouse: role of nerve growth factor and the mitogen-activated protein kinase pathway.** *Brain Res* 2000, **876**:48–54.
50. Hylden JLK, Wilcox GL: **Intrathecal morphine in mice: a new technique.** *Eur J Pharmacol* 1980, **67**:313–316.
51. Chergui K, Svenningsson P, Greengard P: **Physiological role for casein kinase 1 in glutamatergic synaptic transmission.** *J Neurosci* 2005, **25**:6601–6609.
52. Yoshimura M, Nishi S: **Blind patch-clamp recordings from substantia gelatinosa neurons in adult rat spinal cord slices: pharmacological properties of synaptic currents.** *Neuroscience* 1993, **53**:519–526.

doi:10.1186/1744-8069-10-17

Cite this article as: Kurihara et al.: Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors. *Molecular Pain* 2014 **10**:17.

Experimental Medicine

実験医学

別刷

 羊土社

[発行元]

株式会社 羊土社

〒101-0052

東京都千代田区神田小川町2-5-1

TEL 03(5282)1211(代表)

FAX 03(5282)1212

E-mail eigyo@yodosha.co.jp

URL <http://www.yodosha.co.jp/>

© YODOSHA CO., LTD.

本誌に掲載する著作物の複製権・上映権・譲渡権・公衆送信権(送信可能化権を含む)は(株)羊土社が保有します。本誌を無断で複製する行為(コピー、スキャン、デジタルデータ化など)は、著作権法上での限られた例外(私的使用のための複製など)を除き禁じられています。研究活動、診療を含み業務上使用する目的で上記の行為を行うことは大学、病院、企業などにおける内部的な利用であっても、私的使用には該当せず、違法です。また私的使用のためであっても、代行業者等の第三者に依頼して上記の行為を行うことは違法となります。

JCOPY <(社)出版者著作権管理機構 委託出版物>本誌の無断複製は著作権法上での例外を除き禁じられています。複写される場合は、そのつと事前に、(社)出版者著作権管理機構(TEL 03-3513-6969、FAX 03-3513-6979、e-mail:info@jcopy.or.jp)の許諾を得てください。

《注目の標的からの創薬展開》

2. キナーゼの多彩な立体構造を標的とした創薬

喜井 勲, 萩原正敏

キナーゼは細胞内において多彩な立体構造をとっている。創薬研究で活用されている精製キナーゼの立体構造情報は、キナーゼの1つの側面を表したに過ぎない。そのため、精製キナーゼを用いた化合物スクリーニングでは、多彩な立体構造を標的とする阻害剤は見落とされてきた。このような新しいタイプの阻害剤は、細胞を用いた評価系においてのみヒットすると思われる。本稿では、細胞内のキナーゼを標的とした創薬研究について概説する。後半では、われわれが細胞を用いた化合物スクリーニングによって見出したキナーゼのフォールディング中間体を特異的に阻害する化合物について紹介する。

はじめに

キナーゼは創薬研究において最も注目されている分子であると言っても過言ではない。2001年に米国で発売された慢性骨髄性白血病治療薬グリベック[®]（一般名：イマチニブ、チロシンキナーゼABL阻害剤）は、瞬く間に売り上げを伸ばし、抗がん剤市場最大の牽引役となった。世界のキナーゼ阻害剤市場は、2011年に291億ドルに達した。今後も6.7%の年平均成長率が見込まれており、2016年までに402億ドルの市場規模に

達すると予測されている。最近では、2012年11月にJAK3阻害剤（tofacitinib：トファシチニブ）が関節リウマチに対する治療薬としてFDA（米国食品医薬品局）に承認された。2013年7月には、B細胞性悪性疾患に対する治療薬としてチロシンキナーゼBTKに対する阻害剤（ibrutinib：イブルチニブ）の新薬申請がFDAに提出された。

キナーゼ創薬研究は、キナーゼの立体構造情報から化合物を設計するメディシナルケミストリーが主戦場であり、阻害活性や生体適応性（経口吸収性、代謝安

【キーワード&略語】

フォールディング中間体, セルベーススクリーニング, タイプゼロキナーゼ阻害剤

CDC37 : cell division cycle 37

DYRK : dual-specificity tyrosine-phosphorylation-regulated kinase

FINDY : folding intermediate-selective inhibitor of DYRK1A

HSP90 : heat shock protein 90

INDY : inhibitor of DYRK

NFAT : nuclear factor of activated T-cells

PAINS : pan assay interference compounds

PER : Period

Drug development targeting the diverse structures of kinase

Isao Kii/Masatoshi Hagiwara : Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University (京都大学大学院医学研究科生体構造医学講座形態形成機構学)




図1 タイプ別キナーゼ阻害剤

タイプ1阻害剤は、活性型キナーゼのATP結合部位を標的にし、タイプ2阻害剤は、不活性型キナーゼのATP結合部位を標的としている。また、ATP結合部位以外に結合し、キナーゼを不活性状態に保つアロステリック阻害剤（タイプ3や4）などがある

定性など)の向上をめざしたドラッグデザインが行われてきている。キナーゼ阻害剤を設計するうえで、阻害剤結合領域(ATP結合部位)の立体構造を知ることが重要であると考えられている。しかしながら、創薬で活用されているキナーゼの立体構造情報が、細胞内のキナーゼの構造を反映しているとは限らない(後述)。

多くのキナーゼは不活性型と活性型の平衡状態にあることが示されている。増殖因子による刺激や、上流キナーゼによるリン酸化を受けることで活性型となり、特異的な基質をリン酸化してシグナルを下流に伝える。キナーゼ阻害剤はその阻害様式によって、活性型のATP結合部位を標的としたタイプ1阻害剤、不活性型のATP結合部位を標的としたタイプ2阻害剤、そしてATP結合部位以外のアロステリック部位を標的としたタイプ3や4阻害剤(アロステリック阻害剤)に分類される(図1)^{1) 2)}。

本稿では、メディシナルケミストではない、ケミカルバイオロジーを専門とする基礎研究者の視点からのキナーゼ創薬研究の方法論について概説し、上記の分類に当てはまらない新しいタイプの阻害剤についてのわれわれの研究を紹介する。

1 in vitro アッセイを中心としたこれまでの創薬研究

多くのキナーゼ阻害剤は、精製されたキナーゼタンパク質を用いた試験管内評価系によって同定された。キナーゼと化合物を混合し、そこにATPと基質となるペプチドを加える。キナーゼが活性を有していれば、ATPを消費しADPを産生するのに伴い、基質ペプチドがリン酸化される。この際、³²P標識したATPを用いれば、基質ペプチドのリン酸化を直接定量することが可能である。また、消費されたATPや産生されたADPの量を、ATP要求性ルシフェラーゼの発光として間接的に定量することによって、キナーゼの活性を評価する系も確立されている。この評価系は、ハイスループットスクリーニングへ適応でき、多くの創薬研究の現場で使われてきた。

一方で、ヒット化合物のうち、すべてが有用な阻害剤となることはまれである。ヒット化合物が生きた細胞内のキナーゼを阻害するかを評価してみると、阻害活性を示すものと、示さないものにわかれる。前者のような化合物は、疾患モデル動物などで薬効を検証する。




図2 キナーゼの自己リン酸化

キナーゼは、活性化のために自分自身をリン酸化する「自己リン酸化」を触媒する場合がある。自己リン酸化は、分子間と分子内に分類される

方、後者のような化合物が得られる要因としては、

①親水性が高い化合物のため、細胞膜を通過できない。
②疎水性が高すぎるため、細胞培養液に溶解せず、細胞までたどり着かない。

③細胞内に入るが、標的キナーゼに結合できない。などが考えられる。①と②は、化合物の構造を改良することで対処可能な場合がある。③が起こる要因として、スクリーニングで用いる精製キナーゼの立体構造と、細胞内での立体構造が異なる可能性が考えられる。精製キナーゼは、主に大腸菌や昆虫細胞で発現させて精製しているため、哺乳動物細胞内でフォールディングされたキナーゼと同じ立体構造をとるとは限らない。また、細胞内ではキナーゼにさまざまなタンパク質分子などが結合しているため、それらの分子の結合が立体構造に影響を及ぼす可能性もある。さらに細胞内の塩濃度などを含めた環境は、スクリーニングのバッファー条件とは異なる。このように細胞内は複数の要因が複雑に影響しあっており、注意が必要である。

このような背景のなか、われわれのグループを含めた複数の研究グループは、生きた細胞を用いたキナーゼ阻害剤スクリーニング系を構築してきた。この背景には、マルチウェル発光検出装置や、マルチカラー蛍光イメージを全自動でハイスループットに取得可能なハイコンテンツ画像解析システムなどのスクリーニング装置の発展がある³⁾。現状では、さまざまなキナーゼに対して適応可能な簡便なセルベーススクリーニング系はほとんどなく、個別のキナーゼと目的に応じて系を構築する必要がある。

2 生きた細胞内のキナーゼを標的とした創薬研究

セルベーススクリーニング系の構築では、まず使用する細胞を選択する。製薬企業の多くは、維持の容易さや、遺伝子導入の簡便さ、マルチウェルプレートへの接着性のよさなどから、CHO細胞を利用している。われわれは、やはり遺伝子導入の容易さからHEK293細胞を用いているが、接着性はあまり高くないため、ポリエチレンイミンコートしたプレートを用いている。

キナーゼの活性を細胞内で評価するためには、そのキナーゼが基質とするタンパク質などのリン酸化を検出することで、間接的に標的キナーゼの活性を測定する。この場合、標的キナーゼと基質の両方を細胞に過剰発現させておけば、ほかの内在性キナーゼなどの影響を受けにくい。ただし、標的キナーゼ以外によってもリン酸化を受ける場合や、全く異なるメカニズムによりリン酸化が調節されている場合は、標的キナーゼ以外(標的キナーゼを活性化するカスケードの上流に位置するキナーゼなど)に対する阻害剤が得られる可能性も考慮する必要がある。

一方で、キナーゼは、活性化のために自分自身をリン酸化する「自己リン酸化」を触媒する場合がある⁴⁾。自己リン酸化は、分子間と分子内に分類される(図2)。分子間自己リン酸化では、たとえば、受容体型チロシンキナーゼの細胞外ドメインにリガンドが結合し、受容体が二量体化され、細胞内のチロシンキナーゼドメインが近接し、その結果、お互いがリン酸化されることで、活性化が起こる。一方、分子内自己リン酸化では、キナーゼは一分子内において、自分自身をリン酸化する。分子内自己リン酸化は、キナーゼの活性維持

や安定性に関与することが多く、さまざまなキナーゼにおいて分子内自己リン酸化が報告されている^{5)~12)}。

自己リン酸化は、ほかのキナーゼによって触媒されることはないため、標的キナーゼに対して特異性の高い阻害剤をスクリーニングする際には有効である。しかしながら、特に分子内自己リン酸化には、HSP90やCDC37のような分子シャペロンが関与することが報告されており^{13)~15)}、これらシャペロンに対する阻害剤が得られる可能性を考慮すべきである。シャペロンを阻害する場合は、細胞内でのほかのキナーゼに対しても影響が出る可能性がある。

3 細胞内での基質リン酸化の検出

一般的には、リン酸化されたアミノ酸残基を特異的に認識する抗体を用いて、基質のリン酸化を検出する。細胞抽出液を用いる場合は、ウェスタンブロット法以外にも、ELISA、AlphaScreenテクノロジー^{※1}、時間分解蛍光共鳴エネルギー移動 (TR-FRET) を用いた検出系などがあげられる。細胞を固定し、抗体染色により基質のリン酸化を検出する場合には、通常の蛍光免疫細胞染色のほかに、*in situ* proximity ligation assay^{※2}などの高感度な方法を用いて、マルチカラーハイコンテンツ画像解析システムを用いたスクリーニングが可能である。

しかしながら、リン酸化された基質を認識する抗体が簡単に手に入るとは限らない。そのような場合には、フォスタグ (Phos-tag[®])^{※3}などを用いて、リン酸化によって起こる基質のSDS-PAGEでの移動度の変化をみることで、間接的にリン酸化を評価することも可能である。

基質のなかには、リン酸化によりその細胞内局在が変化するものがある。たとえば、転写活性化因子NFATやサーカディアンリズムにかかわるPERなどがあげられる。このような基質に対する特異的な抗体を用いて細胞内局在を可視化し、ハイコンテンツ画像解析システムを用いてスクリーニングを行うことが可能である。また、抗体染色にかかる手間を省くために、基質に蛍光タンパク質やHaloTag[®]^{※4}などを融合させたものを細胞に発現させて、検出する方法もある。HaloTagでは、任意の蛍光プローブなどを導入することが可能であるため、検出系の自由度が高い¹⁶⁾。

基質の安定性がリン酸化に依存することもある。こ

の場合、基質タンパク質量を定量することで、間接的に標的キナーゼの活性を評価することができる。タンパク質量を定量化する方法としては、ウェスタンブロット、ELISAなどの方法もあるが、基質と蛍光もしくは発光タンパク質の融合タンパク質を細胞に発現させ、その蛍光もしくは発光量で定量することでスループット性を高めることができる。

4 擬陽性ヒット化合物の考慮

スクリーニングでは、必ず擬陽性のヒットする可能性を考慮に入れる必要がある。蛍光でのスクリーニングでは、化合物自身がつ強い蛍光やUV吸収が結果に影響することがある。解決策としては、可能な限り長波長側 (近赤外側) の吸収スペクトルを有する蛍光タンパク質を利用することである。長波長側での吸収や蛍光を示す化合物はそれほど多くない。また、蛍光ではなく、発光に検出系を切り替える方法もある。しかしながら、化合物が発光タンパク質の機能を阻害

※1 AlphaScreenテクノロジー

異なる標的分子を補足したビーズ同士の距離が近接したときにのみ起こる化学エネルギー移動を、発光により検出することで、標的分子間の相互作用を定量する技術である。標的分子として抗体を用いることで、細胞抽出液中の基質のリン酸化を定量解析することが可能である。

※2 proximity ligation assay

オリゴヌクレオチドが結合した2分子間の距離が近接したとき、これらのオリゴヌクレオチドがハイブリダイズすることで、核酸合成・伸長反応が起こる。この増幅された核酸を標識することで、分子間相互作用を検出する。標的分子として抗体を用いることで、細胞内での基質のリン酸化を定量解析できる。

※3 フォスタグ

2価のリン酸モノエステルアニオンと強く結合する機能性低分子である。フォスタグを架橋したビオチン、アクリルアミドゲル、アガロースなどが市販されており、リン酸化タンパク質やペプチドの分離・精製・検出が可能である。

※4 HaloTag

HaloTag[®]タンパク質 (分子量33 kDa) と低分子HaloTag[®]リガンドの特異的な共有結合を利用したタンパク質の標識技術である。細胞に発現させたHaloTag[®]融合タンパク質を、さまざまな化学修飾が施された低分子HaloTag[®]リガンドによって標識することで、任意のタンパク質を検出することが可能である。